The role of small airways in lung disease

Respiratory Medicine

Volumn 96, Issue 2, 2002, Pages 67-80

  Shaw, R J ^a   Djukanovic, R ^b   Tashkin, D P ^c   Millar, A B ^d   Du Bois, R M ^e   Corris, P A ^f  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SOUTHMEAD HOSPITAL   (United Kingdom)

^e ROYAL BROMPTON HOSPITAL   (United Kingdom)

^f FREEMAN HOSPITAL   (United Kingdom)

Author keywords

Asthma; Chronic obstructive pulmonary disease; Interstitial lung disease; Obliterative bronchiolitis; Small airways

Indexed keywords

AZATHIOPRINE; BECLOMETASONE DIPROPIONATE; BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID; CYCLOSPORIN; FLUORINATED HYDROCARBON; FLUTICASONE PROPIONATE; GAMMA INTERFERON 1B; GAMMA INTERFERON DERIVATIVE; GANCICLOVIR; HELIUM; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RAPAMYCIN; UNCLASSIFIED DRUG;

AIRWAY OBSTRUCTION; ASTHMA; AUTOPSY; BRONCHIOLITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; IDIOPATHIC DISEASE; INFLAMMATION; LUNG DISEASE; LUNG FIBROSIS; MORBIDITY; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; SARCOIDOSIS; SIDE EFFECT; SMALL AIRWAY DISEASE; SPUTUM ANALYSIS; STRUCTURE ACTIVITY RELATION; TRANSBRONCHIAL BIOPSY;

EID: 0036486544     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1053/rmed.2001.1216     Document Type: Review

References (130)

1. Hamid Q, Song Y, Kotsimbos TC, et al. Inflammation of small airways in asthma. J Allergy Clin Immunol 1997; 100: 44-51.
2. Macklem PT, Mead J. Resistance of central and peripheral airways measured by a retrograde catheter. J App] Physiol 1967; 22: 395-401.
3. Evans DJ, Green M. Small airways: a time to revisit? Thorax 1998; 53: 629-630.
4. Macklem PT. The physiology of small airways. Am J Respir Crit Care Med 1998; 157: S181-S183.
5. Vignola AM, Bousquet J, Chanez P, et al. Assessment of airway inflammation in asthma. Am J Respir Crit Care Med 1998; 157: S184-S187.
6. Busse WW. Inflammation in asthma: the cornerstone of the disease and target of therapy. J Allergy Clin Immunol 1998; 102: S17-S22.
7. Howarth P. Small airway inflammation and asthma. Int J Clin Pract 1998; 96(Suppl): 15-22.
8. Roche WR. Inflammatory and structural changes in the small airways in bronchial asthma. Am J Respir Crit Care Med 1998; 157: S191-S194.
9. Kraft M. The distal airways: are they important in asthma? Eur Respir J 1999; 14: 1403-1417.
10. Carroll N, Elliot J, Morton A, James A. The structure of large and small airways in nonfatal and fatal asthma. Am Rev Respir Dis 1993; 147: 405-410.
11. Synek M, Beasley R, Frew AJ, et al. Cellular infiltration of the airways in asthma of varying severity. Am J Respir Crit Care Med 1996; 154: 224-230.
12. Saetta M, Di Stefano A, Rosina C, Thiene G, Fabbri LM. Quantitative structural analysis of peripheral airways and arteries in sudden fatal asthma. Am Rev Respir Dis 1991; 143: 138-143.
13. Beasley R, Roche WR, Roberts JA, Holgate ST. Cellular events in the bronchi in mild asthma and after bronchial provocation. Am Rev Respir Dis 1989; 139: 806-817.
14. Roche WR, Beasley R, Williams JH, Holgate ST. Subepithelial fibrosis in the bronchi of asthmatics. Lancet 1989; 1: 520-524.
15. Takizawa T, Thurlbeck WM. Muscle and mucous gland size in the major bronchi of patients with chronic bronchitis, asthma, and asthmatic bronchitis. Am Rev Respir Dis 1971; 104: 331-336.
16. Heard BE, Hossain S. Hyperplasia of bronchial smooth muscle in asthma. J Pathol 1972; 110: 319-331.
17. Li X, Wilson JW. Increased vascularity of the bronchial mucosa in mild asthma. Am J Respir Crit Care Med 1997; 156: 229-233.
18. Cosio M, Ghezzo H, Hogg JC, et al. The relations between structural changes in small airways and pulmonary-function tests. N Engl J Med 1978; 298: 1277-1281.
19. Culpitt SV, Rogers DF. Evaluation of current pharmacotherapy of chronic obstructive pulmonary disease. Expert Opin Pharmacother 2000; 1: 1007-1020.
20. Barnes PJ. Novel approaches and targets for treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: S72-S79.
21. Niewoehner DE, Cosio MG. Chronic obstructive lung disease: the role of airway disease, with special emphasis on the pathology of small airways. Monogr Pathol 1978; 19: 160-179.
22. Hogg JC, Macklem PT, Thurlbeck WM. Site and nature of airway obstruction in chronic obstructive lung disease. N Engl J Med 1968; 278: 1355-1360.
23. Spain DM, Kaufman G. The basic lesion in chronic pulmonary emphysema. Am Rev Tuberc 1953; 68: 24-30.
24. Cosio MG, Hale KA, Niewoehner DE. Morphologic and morphometric effects of prolonged cigarette smoking on the small airways. Am Rev Respir Dis 1980; 122: 265-271.
25. Wright JL, Hobson JE, Wiggs B, Pare PD, Hogg JC. Airway inflammation and peribronchiolar attachments in the lungs of nonsmokers, current and ex-smokers. Lung 1988; 166: 277-286.
26. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-α in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996; 153: 530-534.
27. Jeffery PK. Structural and inflammatory changes in COPD: a comparison with asthma. Thorax 1988; 53: 129-136.
28. Lympany PA, du Bois RM. Diffuse lung disease: product of genetic susceptibility and environmental encounters. Thorax 1997; 52: 92-94.
29. Chung MP, Rhee CH. Airway obstruction in interstitial lung disease. Curr Opin Pulm Med 1997; 3: 332-335.
30. DePaso WJ, Winterbauer RH. Interstitial lung disease. Dis Mon 1991; 37: 61-133.
31. Raghu G. Interstitial lung disease: a diagnostic approach. Are the CTscan and lung biopsy indicated in every patient? Am J Respir Crit Care Med 1995; 151: 909-914.
32. Hoffman EA, McLennan G. Assessment of the pulmonary structure-function relationship and clinical outcomes measures: quantitative volumetric CT of the lung. Acad Radiol 1997, 4: 758-776.
33. Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994; 150: 967-972.
34. Turner-Warwick M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis: response to corticosteroid treatment and its effect on survival. Thorax 1980; 35: 593-599.
35. Ryu JH, Colby TV, Hartman TE. Ideopathic pulmonary fibrosis: current concepts. Mayo Clin Proc 1998; 73: 1085-1101.
36. Cherniack RM, Crystal RG, Kalica AR. NHLBI Workshop summary. Current concepts in idiopathic pulmonary fibrosis: a road map for the future. Am Rev Respir Dis 1991; 143: 680-683.
37. Fulmer JD, Roberts WC, von Gal ER, Crystal RG. Small airways in idiopathic pulmonary fibrosis. Comparison of morphologic and physiologic observations. J Clin Invest 1977; 60: 595-610.
38. Vaillant P, Menard O, Vignaud JM, Martinet N, Martinet Y. The role of cytokines in human lung fibrosis. Monaldi Arch Chest Dis 1996; 51: 145-152.
39. Kuhn C. The pathogenesis of pulmonary fibrosis. Monogr Pathol 1993; 36: 78-92.
40. Winterbauer RH, Hammar SP, Hallman KO, et al. Diffuse interstitial pneumonitis. Clinicopathologic correlations in 20 patients treated with prednisone/azathioprine. Am J Med 1978; 65: 6 61-672.
41. Hansell DM, Milne DG, Wilsher ML, Wells AU. Pulmonary sarcoidosis: morphologic associations of airflow obstruction at thin-section CT. Radiology 1998; 209: 697-704.
42. du Bois RM. The alveolar macrophage in sarcoidosis. Sarcoidosis 1990; 7: 15-18.
43. Schlesinger C, Meyer CA, Veeraraghavan S, Koss MN. Constrictive (obliterative) bronchiolitis: diagnosis, etiology, and a critical review of the literature. Ann Diagn Pathol 1998; 2: 321-334.
44. Colby TV Bronchiolitis. Pathologic considerations. Am J Clin Pathol 1998; 109: 101-109.
45. Hansell DM, Rubens MB, Padley SP, Wells AU. Obliterative bronchiolitis: individual CT signs of small airways disease and functional correlation. Radiology 1997; 203: 721-726.
46. Scott JP, Peters SG, McDougall JC, Beck KC, Midthun DE. Posttransplantation physiologic features of the lung and obliterative bronchiolitis. Mayo Clin Proc 1997; 72: 170-174.
47. Keenan RJ, Bruzzone P, Paradis IL, et al. Similarity of pulmonary rejection patterns among heart-lung and double-lung transplant recipients. Transplantation 1991; 51: 176-180.
48. Sharples LD, Tamm M, McNeil K, Higenbottam TW, Stewart S, Wallwork J. Development of bronchiolitis obliterans syndrome in recipients of heart-lung transplantation: early risk factors. Transplantation 1996; 61: 560-566.
49. Griffith BP, Paradis IL, Zeevi A, et al. Immunologically mediated disease of the airways after pulmonary transplantation. Ann Surg 1988; 208: 371-378.
50. Milne DS, Gascoigne AD, Wilkes J, et al. The immuno histopathology of obliterative bronchiolitis following lung transplantation. Transplantation 1992; 54: 748-750.
51. Milne DS, Gascoigne AD, Wilkes J, et al. MHC class II and ICAM-1 expression and lymphocyte subsets in transbronchial biopsies from lung transplant recipients. Transplantation 1994; 57: 1762-1766.
52. Zheng L, Walters EH, Ward C, et al. Airway neutrophilia in stable and bronchiolitis obliterans syndrome patients following lung transplantation. Thorax 2000; 55: 53-59.
53. Fisher AJ, Gabbay E, Small T, Doig S, Dark JH, Corris PA. Cross sectional study of exhaled nitric oxide levels following lung transplantation. Thorax 1998; 53: 454-458.
54. Foerster A, Bjortuft O, Geiran O, Rollag H, Leivestad T, Froysaker T. Single lung transplantation. Morphological surveillance by transbronchial biopsy APMIS 1993; 101: 455-466.
55. Holz O, Jörres A, Magnussen H. Monitoring central and peripheral airway inflammation in asthma. Respir Med 2000; 94: S7-S12.
56. Hargreave FE. Induced sputum for the investigation of airway inflammation: evidence for its clinical application. Can Respir J 1999; 6: 169-174.
57. Pavord ID, Pizzichini MM, Pizzichini E, Hargreave FE. The use of induced sputum to investigate airway inflammation. Thorax 1997, 52: 498-501.
58. Pizzichini E, Pizzichini MM, Gibson P, et al. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med 1998; 158: 1511-1517.
59. Olivieri D, D'Ippolito R, Chetta A. Induced sputum: diagnostic value in interstitial lung disease. Curr Opin Pulm Med 2000; 6: 411-414.
60. Hargreave FE, Popov T, Kidney J, Dolovich J. Sputum measurements to assess airway inflammation in asthma. Allergy 1993; 48: 81-83.
61. Fahy JV, Steiger DJ, Liu J, Basbaum CB, Finkbeiner WE, Boushey HA. Markers of mucus secretion and DNA levels in induced sputum from asthmatic and from healthy subjects. Am Rev Respir Dis 1993; 147: 1132-1137.
62. Keatings VM, Barnes PJ. Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjects. Am J Respir Crit Care Med 1997; 155: 449-453.
63. Louis R, Shute J, Biagi S, et al. Cell infiltration, ICAM-1 expression, and eosinophil chemotactic activity in asthmatic sputum. Am J Respir Crit Care Med 1997; 155: 466-472.
64. Louis R, Lau LC, Bron AO, Roldaan AC, Radermecker M, Djukanović R. The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med 2000; 161: 9-16.
65. Pizzichini MM, Pizzichini E, Clelland L, et al. Sputum in severe exacerbations of asthma: kinetics of inflammatory indices after prednisone treatment. Am J Respir Crit Care Med 1997; 155: 1501-1508.
66. Chung KF. Non-invasive biomarkers of asthma. Pediatr Pulmonol 1999; 18(Suppl): 41-44.
67. Turner MO, Johnston PR, Pizzichini E, Pizzichini MM, Hussack PA, Hargreave FE. Anti-inflammatory effects of salmeterol compared with beclomethasone in eosinophilic mild exacerbations of asthma: a randomized, placebo controlled trial. Can Respir J 1998; 5: 261-268.
68. Pizzichini MM, Kidney JC, Wong BJ, et al. Effect of salmeterol compared with bedomethasone on allergen-induced asthmatic and inflammatory responses. Eur Respir J 1996; 9: 449-455.
69. Jatakanon A, Kharitonov S, Lim S, Barnes PJ. Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma. Thorax 1999; 54: 108-114.
70. Lim S, Jatakanon A, John M, et al. Effect of inhaled budesonide on lung function and airway inflammation. Assessment by various inflammatory markers in mild asthma. Am J Respir Crit Care Med 1999; 159: 22-30.
71. Jatakanon A, Lim S, Chung KF, Barnes PJ. An inhaled steroid improves markers of airway inflammation in patients with mild asthma. Eur Respir J 1998; 12: 1084-1088.
72. van Rensen EL, Straathof KC, Veselic-Charvat MA, Zwinderman AH, Bel EH, Sterk PJ. Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma. Thorax 1999; 54: 403-408.
73. Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997; 155: 542-548.
74. Fahy JV, Wong H, Liu J, Boushey HA, Comparison of samples collected by sputum induction and bronchoscopy from asthmatic and healthy subjects. Am J Respir Crit Care Med 1995; 152: 53-58.
75. Holz O, Jörres RA, Koschyk S, Speckin P, Welker L, Magnussen H. Changes in sputum composition during sputum induction in healthy and asthmatic subjects. Clin Exp Allergy 1998; 28: 284-292.
76. Martin RJ. Small airway and alveolar tissue changes in nocturnal asthma. Am J Respir Crit Care Med 1998; 157: S188-S190.
77. Kraft M, Djukanović R, Wilson S, Holgate ST, Martin RJ. Alveolar tissue inflammation in asthma. Am J Respir Crit Care Med 1996; 154: 1505-1510.
78. Kraft M, Martin RJ, Wilson S, Djukanović R, Holgate ST. Lymphocyte and eosinophil influx into alveolar tissue in nocturnal asthma. Am J Respir Crit Care Med 1999; 159: 228-234.
79. Carroll N, Cooke C, James A. The distribution of eosinophils and lymphocytes in the large and small airways of asthmatics. Eur Respir J 1997; 10: 292-300.
80. Kikawada M, Ichinose Y, Miyamoto D, Minemura K, Takasaki M, Toyama K. Peripheral airway findings in chronic obstructive pulmonary disease using an ultrathin bronchoscope. Eur Respir J 2000; 15: 105-108.
81. Takizawa H, Tanaka M, Takami K, et al. Increased expression of inflammatory mediators in small-airway epithelium from tobacco smokers. Am J Physiol Lung Cell Mol Physiol 2000; 278: L906-L913.
82. Fabbri LM, Caramori G, Beghe, Papi A, Ciaccia A. Physiologic consequences of long-term inflammation. Am J Respir Crit Care Med 1998; 157: S195-S198.
83. Cherniack RM. Physiologic diagnosis and function in asthma. Clin Chest Med 1995; 16: 567-581.
84. Sterk PJ, Fabbri LM, Quanjer PH, et al. Airway responsiveness. Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official statement of the European Respiratory Society. Eur Respir J 1993; 16(Suppl): 53-83.
85. Stanescu D, Sanna A, Veriter C, Robert A. Identification of smokers susceptible to development of chronic airflow limitation: a 13-year follow-up. Chest 1998; 114: 416-425.
86. Stanescu D. Small airways obstruction syndrome. Chest 1999; 116: 231-233.
87. Antic R, Macklem PT. The influence of clinical factors on site of airway obstruction in asthma. Am Rev Respir Dis 1976; 114: 851-859.
88. Kamp DW. Physiologic evaluation of asthma. Chest 1992; 101(Suppl): 396S-400S.
89. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85: 751-758.
90. McLean AN, Sproule MW, Cowan MD, Thomson NC. High resolution computed tomography in asthma. Thorax 1998; 53: 308-314.
91. Paganin F, Vignola AM, Seneterre E, Bruel JM, Chanez P, Bousquet J. Heterogeneity of airways obstruction in asthmatic patients using high-resolution computed tomography. Chest 1995; 107(Suppl): 145S-146S.
92. King GG, Muller NL, Pare PD. Evaluation of airways in obstructive pulmonary disease using high-resolution computed tomography. Am J Respir Crit Care Med 1999; 159: 992-1004.
93. Goldin JG, McNitt-Gray MF, Sorenson SM, et al. Airway hyperreactivity: assessment with helical thin-section CT. Radiology 1998; 208: 321-329.
94. Goldin JD, Tashkin DP, Kleerup EC, et al. Comparative effects of hydrofluoroalkane and chlorofluorocarbon beclomethasone dipropionate inhalation on small airways: assessment with functional helical thin-section computed tomography. J Allergy Clin Immunol 1999; 104: S258-S267.
95. McNitt-Gray MF, Goldin JG, Johnson TD, Tashkin DP, Aberle DR. Development and testing of image-processing methods for the quantitative assessment of airway hyperresponsiveness from high-resolution CT images. J Comput Assist Tomogr 1997; 21: 939-947.
96. Kee ST, Fahy JV, Chen DR, Gamsu G. High-resolution computed tomography of airway changes after induced bronchoconstriction and bronchodilation in asthmatic volunteers. Acad Radiol 1996; 3: 389-394.
97. Salvolini L, Bichi Secchi E, Costarelli L, De Nicola M. Clinical applications of 2D and 3D CTimaging of the airways-a review. Eur J Radiol 2000; 34: 9-25.
98. 3He gas. Radiology 1999; 210: 851-857.
99. 3He MRI: preliminary clinical experience in 18 patients with and without lung disease. J Magn Reson Imaging 1997; 7: 538-543.
100. Guenther D, Hanisch G, Kauczor HU. Functional MR imaging of pulmonary ventilation using hyperpolarized noble gases. Acta Radiol 2000; 41: 519-528.
101. Kauczor H, Surkau R, Roberts T. MRI using hyperpolarized noble gases. Eur Radiol 1998; 8: 820-827.
102. Shaw RJ, Waller JF, Hetzel MR, Clark TJ. Do oral and inhaled terbutaline have different effects on the lung? Br J Dis Chest 1982; 76: 171-176.
103. Barnes PJ. Efficacy of inhaled corticosteroids in asthma. J Allergy Clin Immunol 1998; 102: 531-538.
104. British Asthma Guidelines Co-ordinating Committee. British guidelines on asthma management: 1995; review and position statement. Thorax 1997; 52: S1-S24.
105. National Asthma Education and Prevention Programme. Expert Panel Report 2. Clinical Practice Guidelines, 1997. NIH Publication No. 97-4051.
106. Barnes PJ, Jonsson B, Klim J. The costs of asthma. Eur Respir J 1996; 9: 636-642.
107. Newman SP. A comparison of lung deposition patterns between different asthma inhalers. J Aerosol Med 1995; 8: S21-S26.
108. Global Initiative for Chronic Obstructive Lung Diseases. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. USDHHS, 2001. NIH Publication No. 2701A.
109. Raghu G, Depaso WJ, Cain K, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo controlled clinical trial. Am Rev Respir Dis 1991; 144: 291-296.
110. Johnson MA, Kwan S, Snell NJ, Nunn AJ, Darbyshire JH, Turner-Warwick M. Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 1989; 44: 280-288.
111. Mapel DW, Samet JM, Coultas DB. Corticosteroids and the treatment of idiopathic pulmonary fibrosis. Past, present, and future. Chest 1996; 110: 1058-1067.
112. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161: 646-664.
113. Ziesche RE, Hofbauer K, Wittmann K, Petkov V, Block LH. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999; 341: 1264-1269.
114. Ploysongsang Y, Roberts RD. The pathophysiology and response to steroid therapy in sarcoidosis. Respiration 1986; 49: 204-215.
115. Gottlieb JE, Israel HL, Steiner RM, Triolo J, Patrick H. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest 1997; 111: 623-631.
116. Johns CJ, Zachary JB, Ball WC Jr. A ten-year study of corticosteroid treatment of pulmonary sarcoidosis. Johns Hopkins Med J 1974; 134: 271-283.
117. du Bois RM, Greenhalgh PM, Southcott AM, Johnson NM, Harris TA. Randomized trial of inhaled fluticasone propionate in chronic stable pulmonary sarcoidosis: a pilot study. Eur Respir J 1999; 13: 1345-1350.
118. Selroos O, Lofroos AB, Pietinalho A, Niemisto M, Riska H. Inhaled budesonide for maintenance treatment of pulmonary sarcoidosis. Sarcoidosis 1994; 11: 126-131.
119. Zych D, Pawlicka L, Zielinski J. Inhaled budesonide vs prednisone in the maintenance treatment of pulmonary sarcoidosis. Sarcoidosis 1993; 10: 56-61.
120. Erkkila S, Froseth B, Hellstrom PE, et al. Inhaled budesonide influences cellular and biochemical abnormalities in pulmonary sarcoidosis. Sarcoidosis 1988; 5: 106-110.
121. Gupta SK. Treatment of sarcoidosis patients by steroid aerosol: a ten-year prospective study from Eastern India. Sarcoidosis 1989; 6: 51-54.
122. Pietinalho A, Tukiainen P, Haahtela T, Persson T, Selroos O. Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis: a double-blind, placebo-controlled multi-center study. Finnish Pulmonary Sarcoidosis Study Group. Chest 1999; 116: 424-431.
123. Alberts C, van der Mark TW, Jansen HM. Inhaled budesonide in pulmonary sarcoidosis: a double-blind, placebo-controlled study Dutch Study Group on Pulmonary Sarcoidosis. Eur Respir J 1995; 8: 682-688.
124. Milman N, Graudal N, Grode G, Munch E. No effect of high-dose inhaled steroids in pulmonary sarcoidosis: a double-blind, placebo-controlled study. J Intern Med 1994; 236: 285-290.
125. Dusmet M, Maurer J, Winton T, Kesten S. Methotrexate can halt the progression of bronchiolitis obliterans syndrome in lung transplant recipients. J Heart Lung Transplant 1996; 15: 948-954.
126. Reichenspurner H, Girgis RE, Robbins RC, et al. Stanford experience with obliterative bronchiolitis after lung and heart-lung transplantation. Ann Thoroc Surg 1996; 62: 1467-1472: discussion 1472-1473.
127. Soghikian MV, Valentine VG, Berry GJ, Patel HR, Robbins RC, Theodore J. Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients. J Heart Lung Transplant 1996; 15: 881-887.
128. Clelland CA, Higenbottam TW, Monk JA, Scott JP, Smyth RL, Wallwork J. Bronchoalveolar lavage lymphocytes in relation to transbronchial lung biopsy in heart-lung transplants. Transplant Proc 1990; 22: 1479.
129. Takao M, Higenbottam TW, Audley T, Otulana BA, Wallwork J. Effects of inhaled nebulized steroids (budesonide) on acute and chronic lung function in heart-lung transplant patients. Transplant Proc 1995; 27: 1284-1285.
130. Speich R, Boehler A, Russi EW, Weder W. A case report of a double-blind, randomized trial of inhaled steroids in a patient with lung transplant bronchiolitis obliterans. Respiration 1997; 64: 375-380.